Catalyst News and Research

RSS

Americans with Disabilities Act turns 20

Several news outlets note the 20th anniversary Monday of the Americans With Disabilities Act.

27 Jul 2010

Scientists discover mechanism of herpes virus cell entry machinery

The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.

27 Jul 2010

Cardiva Medical, Advanced Vascular Dynamics sign agreement to distribute hemostasis products

Cardiva Medical, Inc. announced today that it has signed an agreement with Advanced Vascular Dynamics to distribute several products used for postcatheterization femoral and radial artery hemostasis in the U.S.

27 Jul 2010

IDEXX Laboratories second-quarter 2010 revenues increase 6% to $281.5 million

IDEXX Laboratories, Inc., today reported that revenues for the second quarter of 2010 increased 6% to $281.5 million, from $265.7 million for the second quarter of 2009. Organic revenue growth, as defined below, was 5%. Earnings per diluted share for the quarter ended June 30, 2010 increased 13% to $0.62, compared to $0.55 for the same period in the prior year.

23 Jul 2010

Eurotech enters multiple contracts with DynaVox for Catalyst embedded computers

Eurotech, a leading supplier of embedded technologies, products, and systems, today announces multiple contracts with DynaVox to deliver the Catalyst LP and Catalyst Module embedded computers for the DynaVox V, Vmax and Xpress™ alternative augmentative communication (AAC) devices. The combined value of these contracts is nearly 4.2M USD, with deliveries to be made in 2010 and 2011.

20 Jul 2010

MDMA (Ecstasy) holds promise for chronic treatment-resistant PTSD

MDMA (-3,4-methylenedioxymethamphetamine, also known as Ecstasy), may one day offer hope for individuals with posttraumatic stress disorder (PTSD), even people for whom other treatments have failed. Clinical trial results out today in the Journal of Psychopharmacology, published by SAGE, suggests that MDMA can be administered to subjects with PTSD without evidence of harm and could offer sufferers a vital window with reduced fear responses where psychotherapy can take effect.

20 Jul 2010

Mizzou Advantage researchers examine food-related issues to find solutions for future

Many of society's most challenging health issues, including obesity, nutritional shortages and chronic disease, are related to food. University of Missouri researchers are examining the multiple facets of food and how it impacts our lives - from medicine and research to policy and law to education and business.

15 Jul 2010

BioImagene licenses Olympus patents in digital pathology, virtual microscopy

Olympus America Inc. has signed a nonexclusive worldwide licensing agreement with BioImagene, Inc. of Sunnyvale, California, allowing BioImagene to access an extensive portfolio of Olympus patents in the field of digital pathology and virtual microscopy. This is the most recent of several licenses that Olympus has granted for the technologies, which are considered critical for developing future digital imaging and data handling systems for pathology.

From Evident Corporation - Life Sciences 12 Jul 2010

Investment report on Catalyst Pharmaceutical Partners

MicroStockProfit.com announces an investment report featuring Catalyst Pharmaceutical Partners Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

12 Jul 2010

New website presenting latest in Alzheimer's disease research unveiled at AAICAD 2010

A new website showcasing the latest in Alzheimer's disease research and science - www.alz.org/research - is being unveiled at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu.

12 Jul 2010

BRAIN AG acquires a minority share in Enzymicals AG

BRAIN AG, one of the leading European white biotechnology companies, has acquired a minority share in Enzymicals AG. This biotechnology company was founded in 2009 as a spin-off by a management team from the workgroup led by Prof. Dr. Uwe Bornscheuer from Ernst-Moritz-Arndt University Greifswald with support from the EXIST-Programme of the Federal Ministry for Economy and Technology.

12 Jul 2010

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

Catalyst Pharmaceutical Partners, Inc. today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management.

9 Jul 2010

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

A University of Oklahoma researcher is developing a novel therapy for Alzheimer's disease using "biopharmaceutical proteases" to attack the toxic plaque that builds up in the brain of an Alzheimer's patient-an approach that he predicts will be lower in cost and higher in effectiveness than current therapies.

9 Jul 2010

American, Canadian officials discuss global health developments at recent G8, G20 summits

The recent G8 summit in Canada's Muskoka region took an important step forward in improving maternal and child health in developing countries, Canadian and American officials said at a forum Wednesday in Washington, DC.

9 Jul 2010

Stand-By Systems now eligible to sell products to federal government

Emerging Healthcare Solutions, Inc. disclosed today that Stand-By Systems has favorably completed their US Government Central Contractor Registration and is now eligible to sell their breakthrough products to the federal government. EHSI has verified the federal eligibility as part of their due diligence related to an option with Stand-By Systems (SBS), owner of the FDA approved SBS 1615 catalytic oxygen generator and associated systems. The option agreement allows EHSI management to perform due diligence prior to finalizing a definitive agreement.

7 Jul 2010

Aquapharm Biodiscovery signs research agreement with AMRI

Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm's marine natural products library derived from its extensive collection of marine micro-organisms.

7 Jul 2010

Creativity can be enhanced by experiencing different cultures

Creativity can be enhanced by experiencing cultures different from one's own, according to a study in Personality and Social Psychology Bulletin (published by SAGE).

2 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

New chemical method for drug design, agrichemicals

University of Delaware scientist Donald Watson is part of a research team that has discovered an easier method for incorporating fluorine into organic molecules, giving chemists an important new tool in developing materials ranging from new medicines to agricultural chemicals.

30 Jun 2010

Genomatica achieves two key commercialization milestones

Genomatica announced today that it has achieved two key commercialization milestones ahead of schedule. First, the company achieved pilot-scale validation, at 3,000 liters, of the manufacturability and commercial viability of a 'green' version of 1,4-butanediol (BDO), its first commercial product. And second, the company confirmed the accelerated development time and reduced development and production costs made possible through use of its technology platform, from concept to commercialization.

30 Jun 2010